Emergent BioSolutions logo
Emergent BioSolutions
EBS | NYSE
Chart Builder DCF Calculator
$5.81
+$0.02 (+0.43%)
At close: Nov 16, 2026, 4:00 PM ET
$5.94
+$0.13 (+2.24%)
After-hours: Nov 16, 2026, 6:11 PM ET

Emergent BioSolutions Company Profile

Company profile explained

Company Profile

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.

Key Executives

Name Position
Joseph C. Papa Jr. Chief Executive Officer, President & Director
Assal Hellmer Vice President of Communications
Coleen Glessner Executive Vice President of Quality, Ethics & Compliance
Frank Vargo VP & Treasurer
Jessica Perl Senior Vice President, Corporate Secretary & General Counsel
Michelle Pepin Senior Vice President & Chief Human Resource Officer
Paul Williams Senior Vice President of Products Business
Richard S. Lindahl Executive VP & CFO
Stephanie Duatschek Executive VP & Chief Growth Officer
William Hartzel Senior Vice President of Manufacturing & Bioservices

Latest SEC Filings

Date Type Title
Oct 16, 2026 8-K Current Report
Oct 07, 2026 4 Filing
Oct 05, 2026 4 Filing
Sep 14, 2026 8-K Current Report
Sep 01, 2026 8-K Current Report
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 12, 2026 3 Filing
Aug 06, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
Jul 31, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
Emergent BioSolutions
Emergent BioSolutions logo
Country United States
IPO Date Nov 15, 2006
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 900
CEO Joseph C. Papa Jr.

Contact Details

400 Professional Drive Gaithersburg, Maryland 20879 United States

Stock Details

Ticker Symbol EBS
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001367644
CUSIP Number 29089Q105
ISIN Number US29089Q1058
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.